Selskabets formål er at drive handel med lægemidler og andre dermed beslægtede produkter samt fabrikation og financieringsvirksomhed
| Year | Revenue | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 2024 | 475.1 mio. | 6.2 mio. | 302.1 mio. | 202.6 mio. | 126 | |
CVR: 55742928
Secondary names: ASTRA A/S, ASTRA LÆGEMIDLER A/S, ASTRA-GRUPPEN A/S
Kurt Hungeberg left the board
Charlotte Ivang Ladefoged joined the board
Compared to 406 companies in Engroshandel med medicinalvarer og sygeplejeartikler
Comparison is based on industry median values
AstraZeneca A/S demonstrates a solid financial health with a notable increase in revenue and profit over the past few years. In 2024, the company reported revenue of 475,073,000 DKK and a profit of 6,241,000 DKK, reflecting a growth trend from 391,141,000 DKK in revenue and 16,214,000 DKK in profit in 2023. Despite the revenue growth, profit margins have fluctuated, indicating potential concerns regarding cost management. The equity position has improved, reaching 202,628,000 DKK in 2024, positioning the company favorably within the pharmaceutical wholesale industry. Overall, AstraZeneca A/S is on a positive trajectory, although attention to profit margins and operational efficiency will be crucial moving forward.
AI-generated summary
Companies in the same industry and area
companydata.dk